Summit Therapeutics PLC (NASDAQ:SMMT)‘s stock had its “buy” rating reaffirmed by investment analysts at Oppenheimer Holdings Inc. in a research note issued on Wednesday.

Separately, Zacks Investment Research upgraded shares of Summit Therapeutics PLC from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Friday, February 3rd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $25.00.

Analyst Recommendations for Summit Therapeutics PLC (NASDAQ:SMMT)

Summit Therapeutics PLC (NASDAQ:SMMT) opened at 10.36 on Wednesday. The company’s 50-day moving average price is $12.28 and its 200-day moving average price is $11.16. The firm’s market cap is $128.24 million. Summit Therapeutics PLC has a one year low of $5.31 and a one year high of $19.75.

COPYRIGHT VIOLATION WARNING: “Summit Therapeutics PLC’s (SMMT) “Buy” Rating Reaffirmed at Oppenheimer Holdings Inc.” was posted by Marea Informative and is the property of of Marea Informative. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at

About Summit Therapeutics PLC

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

5 Day Chart for NASDAQ:SMMT

Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.